Third Arc Secures $165M Series A to Advance Novel T-Cell Engager Platform for Cancer and Inflammation
• Third Arc Bio, led by former Johnson & Johnson executives, has raised $165 million in Series A funding to develop multifunctional antibodies for T-cell engagement in solid tumors and inflammatory conditions.
• The company plans an ambitious clinical development program, aiming to advance five therapeutic candidates into clinical trials next year, leveraging their specialized antibody platform technology.
• The funding round was led by Vida Ventures and co-led by Cormorant Asset Management and Hillhouse Investment, with support from founding investor Omega Funds.
© Copyright 2025. All Rights Reserved by MedPath